Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERYC 125 vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-t RNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Treatment of infections caused by susceptible strains of microorganisms (e.g., respiratory tract infections, skin infections, pertussis, diphtheria, syphilis),Off-label: Prokinetic agent for gastroparesis, treatment of delayed gastric emptying
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Primarily hepatic via cytochrome P450 3A4 (CYP3A4) isoenzyme; undergoes demethylation and hydrolysis; major metabolite is desosamine.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
70-90% bound to albumin and alpha-1-acid glycoprotein.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.5-0.9 L/kg; indicates distribution into total body water with some tissue binding.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: ~35% (acid-labile, enteric-coated).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce dose by 50% or extend interval to every 8-12 hours.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 50%. Class C: reduce dose by 75% or avoid use.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
30-50 mg/kg/day orally divided every 6-8 hours; maximum 2 g/day.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific adjustment; monitor for ototoxicity and QT prolongation; consider lower initial dose due to age-related renal decline.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No FDA boxed warning for ERYC 125.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Risk of QT prolongation and ventricular arrhythmias (e.g., torsades de pointes), especially with other QT-prolonging drugs or electrolyte abnormalities,Hepatic impairment: monitor liver function,Potential for drug interactions via CYP3A4 inhibition,May exacerbate myasthenia gravis,Infantile hypertrophic pyloric stenosis (IHPS) risk in neonates
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to erythromycin or any macrolide antibiotic,Concomitant use with CYP3A4 substrates that prolong QT interval (e.g., terfenadine, astemizole, cisapride, pimozide),Pre-existing QT prolongation or cardiac arrhythmia history
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Grapefruit and grapefruit juice should be avoided as they can increase drug levels and risk of toxicity. Food does not significantly alter absorption of the ethylsuccinate formulation, but taking with a high-fat meal may slightly delay absorption. Avoid alcohol as it may increase risk of hepatotoxicity.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Erythromycin, including ERYC 125, has not been associated with major congenital malformations in human studies. However, there is a potential increased risk of pyloric stenosis in infants exposed in utero or postnatally. No known teratogenic effects in first trimester; use in pregnancy is generally considered safe when indicated, especially for infections like chlamydia or syphilis.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Erythromycin is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is considered compatible with breastfeeding by the American Academy of Pediatrics, but may increase the risk of pyloric stenosis in neonates. Monitor for gastrointestinal symptoms in the infant.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No specific dose adjustment is required for pregnancy based on pharmacokinetic changes. However, erythromycin has reduced plasma concentrations in late pregnancy due to increased volume of distribution and clearance, but no dose adjustment is recommended. Standard dosing is used.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
ERYC 125 (erythromycin ethylsuccinate) is a macrolide antibiotic; note that it may prolong QT interval, especially when combined with other QT-prolonging drugs. Avoid use in patients with hepatic impairment or known cholestatic jaundice. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption, but food does not significantly affect the ethylsuccinate formulation.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Take this medication on an empty stomach, at least 1 hour before or 2 hours after a meal.,Avoid grapefruit and grapefruit juice while taking this medicine.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe stomach pain.,Notify your doctor immediately if you experience irregular heartbeat, fainting, or severe diarrhea.,Complete the full course to prevent antibiotic resistance.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERYC 125 vs ALFENTA, answered by our medical review team.
ERYC 125 is a Macrolide Antibiotic that works by Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-t RNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERYC 125 and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERYC 125 is: 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERYC 125 and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERYC 125 is classified as Category C. Erythromycin, including ERYC 125, has not been associated with major congenital malformations in human studies. However, there is a potential increased risk of pyloric stenosis in . ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.